banner
Raf inhibitor CEP-32496 hydrochloride, Purity ≥98%
Inquiry

Cat. No.: X23-10-ZQ973

Raf inhibitor CEP-32496 hydrochloride, Purity ≥98%

Synonym: CEP-32496 hydrochloride; 1227678-26-3; Agerafenib hydrochloride; 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride; 8J0Y5N290S; 1-[3-(6,7-Dimethoxyquinazolin-4-yl)oxyphenyl]-3-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea; Raf inhibitor

  • CAS Number: 1227678-26-3
  • Compound CID: 56954675
img
Product Size
5 mg; 10 mg; 25 mg; 50 mg; 100 mg
Price
Datasheet
MSDS
Properties
Description
CEP-32496 hydrochloride blocks a MAPK/ERK signaling pathway. It targets Abl1, B-Raf, B-Raf (V600E), and c-Kit.
Molecular Weight
553.92
Molecular Formula
C24H23ClF3N5O5
Targets
Abl1: 3 nM (Kd); B-Raf: 36 nM (Kd); B-Raf (V600E): 14 nM (Kd); c-Kit: 2 nM (Kd)
Form
Lyophilized powder
Purity
≥98%
Identity
Confirmed by NMR/HPLC/MS.
Applications
CEP-32496 hydrochloride can be applied to inhibit mutant BRAF (V600E) and explore anti-cancer strategies.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0